ViriMASK

Company Overview

Snapshot

Founded in March 2020 by Prof. Noam Gavriely, ViriMASK operates with 1–10 employees. The company has developed a protective oculo-respirator designed for high-level filtration against micron-sized particles, including bacteria and viruses. In July 2020, ViriMASK announced that its mask blocks 99.25% of coronavirus-sized particles, exceeding the effectiveness of N95 masks.

Business overview

ViriMASK is a Health Tech & Life Sciences company specializing in medical devices, particularly protective respiratory equipment. The company has developed a full-face oculo-respirator designed to provide maximum protection against micron-sized particles, such as bacteria and viruses. Its core technology involves dense filters that retain inhaled and exhaled particles larger than 0.1 microns, coupled with a sealed design that covers the eyes, nose, and mouth to prevent infection and contamination. The mask is designed for comfortable, extended wear with low airflow resistance and can be washed and disinfected. ViriMASK serves healthcare providers and patients, operating within the medical treatment and therapeutics sector.

Strategic signal

In July 2020, ViriMASK announced that its mask blocks 99.25% of coronavirus-sized particles, surpassing the effectiveness of N95 masks. This development signals a significant advancement in personal protective equipment, offering enhanced safety for medical professionals and high-risk individuals. For investors and innovation teams, this indicates ViriMASK's potential to set new standards in respiratory protection and capture a substantial share of the market for high-efficacy masks.

Company Intelligence Q&A

What is ViriMASK's primary product?

ViriMASK's primary product is a protective oculo-respirator designed to offer maximum protection against micron-sized particles, including bacteria and viruses, by covering the eyes, nose, and mouth with a sealed filtering mechanism.

When was ViriMASK founded and by whom?

ViriMASK was founded in March 2020 by Prof. Noam Gavriely.

What was a key development for ViriMASK in July 2020?

In July 2020, ViriMASK announced that its mask blocks 99.25% of coronavirus-sized particles, exceeding the effectiveness of N95 masks.

What was announced regarding the ViriMASK in March 2020?

In March 2020, it was announced that the ViriMASK Protective Oculo-Respirator, developed by HemaClear, covers the eyes, nose, and mouth to protect against coronavirus. The device is washable and reusable, with filters needing replacement after 12 hours of use.

What is the expected production capacity for ViriMASK?

In March 2020, HemaClear, a subsidiary of ViriMASK, planned to start efficacy testing in mid-April and aimed to produce 1,000 units per day, ramping up to 100,000 units per day within four months.